Success Metrics

Clinical Success Rate
79.9%

Based on 135 completed trials

Completion Rate
80%(135/169)
Active Trials
24(11%)
Results Posted
75%(101 trials)
Terminated
34(15%)

Phase Distribution

Ph early_phase_1
2
1%
Ph not_applicable
12
5%
Ph phase_1
37
17%
Ph phase_3
27
12%
Ph phase_4
5
2%
Ph phase_2
120
55%

Phase Distribution

39

Early Stage

120

Mid Stage

32

Late Stage

Phase Distribution203 total trials
Early Phase 1First-in-human
2(1.0%)
Phase 1Safety & dosage
37(18.2%)
Phase 2Efficacy & side effects
120(59.1%)
Phase 3Large-scale testing
27(13.3%)
Phase 4Post-market surveillance
5(2.5%)
N/ANon-phased studies
12(5.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.6%

135 of 174 finished

Non-Completion Rate

22.4%

39 ended early

Currently Active

24

trials recruiting

Total Trials

220

all time

Status Distribution
Active(27)
Completed(135)
Terminated(39)
Other(19)

Detailed Status

Completed135
Terminated34
unknown19
Recruiting12
Active, not recruiting12
Withdrawn5

Development Timeline

Analytics

Development Status

Total Trials
220
Active
24
Success Rate
79.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.0%)
Phase 137 (18.2%)
Phase 2120 (59.1%)
Phase 327 (13.3%)
Phase 45 (2.5%)
N/A12 (5.9%)

Trials by Status

not_yet_recruiting31%
recruiting125%
terminated3415%
unknown199%
withdrawn52%
active_not_recruiting125%
completed13561%

Recent Activity

24 active trials
Showing 5 of 220
recruitingphase_2

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

NCT05773274
recruitingphase_3

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT07218926
recruitingphase_2

Pan Tumor Rollover Study

NCT03899155
recruitingphase_1

Losartan + Sunitinib in Treatment of Osteosarcoma

NCT03900793
terminatedphase_2

Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)

NCT01216371
View all 220 trials

Clinical Trials (220)

Showing 20 of 220 trialsScroll for more
NCT05773274Phase 2

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Recruiting
NCT07218926Phase 3

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

Recruiting
NCT03899155Phase 2

Pan Tumor Rollover Study

Recruiting
NCT03900793Phase 1

Losartan + Sunitinib in Treatment of Osteosarcoma

Recruiting
NCT01216371Phase 2

Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)

Terminated
NCT03141177Phase 3

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Completed
NCT01396408Phase 2

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Active Not Recruiting
NCT03768063Phase 3

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Active Not Recruiting
NCT06390826Phase 2

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Active Not Recruiting
NCT03091192Phase 3

Savolitinib vs. Sunitinib in MET-driven PRCC.

Active Not Recruiting
NCT06948955

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

Unknown
NCT02848768

Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma

Completed
NCT05208047Phase 3

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Recruiting
NCT00715442Phase 2

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

Active Not Recruiting
NCT02231749Phase 3

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Completed
NCT05043090Phase 3

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Active Not Recruiting
NCT03260894Phase 3

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Completed
NCT00510640Phase 2

Thyroid Cancer and Sunitinib

Completed
NCT02555748Phase 4

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

Completed
NCT05477576Phase 3

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
220